Cereno Scientific reports first patient enrolled in Phase II study in PAH with drug candidate CS1 and update timeline for top-line results to Q1 2023
Cereno Scientific (XSAT: CRNO B) today announced that the first patient has been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. Based on the timing of enrollment and several factors mainly related to the activation of clinical sites, the study timeline has been adjusted by about a quarter and top-line results are now estimated for Q1 2023. The number of study sites has been increased to include about 10 clinics across the US with potential for further expansion in order to facilitate meeting the Q1 timeline.“It is great to have the first PAH